On immunotherapies and cancer vaccination protocols: a mathematical modelling approach
/in Dendritic Cells, International Publications /von 2009-05-14 / J. Theor. Biol. 2009 Aug;259(4):820-7Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer
/in Dendritic Cells, Esophageal Carcinoma, International Publications /von 2009-05-14 / Cancer Sci. 2009 Aug;100(8):1502-9Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2009-05-07 / J. Clin. Immunol. 2009 Sep;29(5):657-64Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2009-05-05 / Clin. Cancer Res. 2009 May;15(10):3366-75Tumor vaccines for breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2009-05-01 / Cancer Invest. 2009 May;27(4):361-8Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma
/in Dendritic Cells, International Publications, Malignant Lymphoma /von 2009-05-01 / J. Immunother. 2009 May;32(4):333-40Antitumor vaccines, immunotherapy and the immunological constant of rejection
/in Dendritic Cells, International Publications /von 2009-05-01 / IDrugs 2009 May;12(5):297-301Conditioning vaccination site with irradiated MIP-3alpha-transfected tumor cells enhances efficacy of dendritic cell-based cancer vaccine
/in Dendritic Cells, International Publications /von 2009-05-01 / J. Immunother. 2009 May;32(4):363-9Novel strategies for improved cancer vaccines
/in Dendritic Cells, International Publications /von 2009-05-01 / Expert Rev Vaccines 2009 May;8(5):567-76
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution